The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
RR1:AU
Rights Issue and Shortfall
Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo
Mar. 13, 2018 08:40AM PST
Pharmaceutical InvestingAkcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals (NASDAQ:IONS) today announced the presentation of a poster summarizing results from the completed Phase 1/2 clinical study of AKCEA-APOCIII-LRx at the American College of Cardiology (ACC) Annual Scientific Session & Expo on March 10, 2018, in Orlando, Florida. As quoted in the press release: “We are pleased to …
Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals (NASDAQ:IONS) today announced the presentation of a poster summarizing results from the completed Phase 1/2 clinical study of AKCEA-APOCIII-LRx at the American College of Cardiology (ACC) Annual Scientific Session & Expo on March 10, 2018, in Orlando, Florida.
As quoted in the press release:
“We are pleased to share the outcomes of this AKCEA-APOCIII-LRx study with the ACC community. The data showing significant and sustained reductions of multiple parameters, including ApoC-III and triglyceride levels, underscore the important regulatory role ApoC-III protein plays in controlling lipid levels in blood, and the potentially broad implications that reducing ApoC-III levels could have for cardiovascular health. We look forward to seeing the results from our AKCEA-APOCIII-LRx Phase 2 study in 2019,” said Dr. Louis O’Dea, chief medical officer at Akcea Therapeutics.
Outlook Reports
Featured Pharmaceutical Investing Stocks
Browse Companies
MARKETS
COMMODITIES
| Commodities | |||
|---|---|---|---|
| Gold | 2348.01 | -15.71 | |
| Silver | 28.51 | +0.38 | |
| Copper | 4.37 | +0.11 | |
| Oil | 84.57 | -1.09 | |
| Heating Oil | 2.64 | -0.05 | |
| Natural Gas | 1.71 | -0.06 | |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.